Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest EPS Estimates For The Next Quarter
Below are the top biotechnology stocks on the NASDAQ in terms of earnings estimate for the next quarter.
Biogen Idec (NASDAQ: BIIB) is estimated to post earnings of $2.07 per share in the September quarter. Biogen Idec's trailing-twelve-month revenue is $5.64 billion.
Amgen (NASDAQ: AMGN) is expected to earn $1.80 per share in the September quarter. Amgen's trailing-twelve-month operating margin is 34.08%.
Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ) is likely to earn $1.46 per share in the June quarter. Jazz Pharmaceuticals had $387.20 million in total cash for the latest quarter.
Celgene (NASDAQ: CELG) may earn $1.45 per share in the September quarter. Celgene's PEG ratio is 0.94.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.